Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$25.92 -2.8%	$22.96	$12.21 ▼ $41.31	$783.86M	-0.27	649,273 shs	334,038 shs
AVXL Anavex Life Sciences	$10.98 -0.7%	$8.98	$4.93 ▼ $14.44	$944.71M	0.72	1.19 million shs	762,981 shs
INMB INmune Bio	$2.42 +8.0%	$5.83	$1.89 ▼ $11.64	$52.83M	1.34	850,804 shs	1.97 million shs
VIR Vir Biotechnology	$5.41 -1.5%	$5.14	$4.32 ▼ $14.45	$758.93M	1.22	1.37 million shs	2.07 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-2.85%	-1.07%	+10.82%	+26.13%	-24.78%
AVXL Anavex Life Sciences	-0.72%	-1.17%	+21.59%	+22.68%	+85.47%
INMB INmune Bio	+8.04%	+4.76%	-66.57%	-66.94%	-73.35%
VIR Vir Biotechnology	-1.46%	-4.25%	+3.84%	-1.64%	-47.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	1.6819 of 5 stars	3.4	0.0	0.0	1.3	2.5	0.6
AVXL Anavex Life Sciences	3.9135 of 5 stars	3.7	1.0	4.7	2.5	0.8	0.6
INMB INmune Bio	1.5967 of 5 stars	3.3	1.0	0.0	1.1	1.7	0.6
VIR Vir Biotechnology	3.5901 of 5 stars	3.4	4.0	0.0	2.0	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	63.48% Upside
AVXL Anavex Life Sciences	3.33	Buy	$44.00	300.73% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	660.33% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	459.15% Upside

Current Analyst Ratings Breakdown

Latest INMB, AVXL, VIR, and ANAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$111.87M	6.81	N/A	N/A	$2.33 per share	11.12
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
INMB INmune Bio	$10K	5,706.36	N/A	N/A	$1.45 per share	1.67
VIR Vir Biotechnology	$74.21M	10.08	N/A	N/A	$8.35 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	N/A	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)

Latest INMB, AVXL, VIR, and ANAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	ANAB AnaptysBio	-$1.47	N/A	N/A	N/A	$11.55 million	N/A
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.25	8.25
AVXL Anavex Life Sciences	N/A	6.74	6.74
INMB INmune Bio	N/A	2.64	2.64
VIR Vir Biotechnology	N/A	6.79	6.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
AVXL Anavex Life Sciences	31.55%
INMB INmune Bio	12.72%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
AVXL Anavex Life Sciences	11.40%
INMB INmune Bio	35.70%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
AVXL Anavex Life Sciences	40	85.42 million	75.68 million	Optionable
INMB INmune Bio	10	23.58 million	15.17 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable

INMB, AVXL, VIR, and ANAB Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $19,615.42 in Stock

July 18 at 10:14 PM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $37,174.12 in Stock

July 18 at 10:14 PM | marketbeat.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 3,586 Shares of Stock

July 18 at 10:11 AM | insidertrades.com

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

July 14, 2025 | finance.yahoo.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Raymond James Financial

July 13, 2025 | americanbankingnews.com

Raymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation

July 12, 2025 | msn.com

Vir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Raymond James Financial

July 11, 2025 | marketbeat.com

Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?

July 10, 2025 | zacks.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $32.86 Consensus Price Target from Brokerages

July 10, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?

July 9, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 7, 2025 | marketbeat.com

Vicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

July 3, 2025 | insidertrades.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of Stock

July 2, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of Revenue

June 30, 2025 | marketbeat.com

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

June 25, 2025 | finance.yahoo.com

Janet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 3, 2025 | insidertrades.com

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology

May 29, 2025 | investing.com

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025 | businesswire.com

Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs

May 22, 2025 | fiercebiotech.comF

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

May 22, 2025 | benzinga.com

Vir’s hepatitis B combo falls short in Phase II trial

May 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
By Gabriel Osorio-Mazilli | July 8, 2025
View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

INMB, AVXL, VIR, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

$25.92 -0.76 (-2.85%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$25.93 +0.01 (+0.04%)

As of 07/18/2025 04:33 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Anavex Life Sciences NASDAQ:AVXL

$10.98 -0.08 (-0.72%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$11.01 +0.03 (+0.27%)

As of 07/18/2025 07:51 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

INmune Bio NASDAQ:INMB

$2.42 +0.18 (+8.04%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.36 -0.06 (-2.69%)

As of 07/18/2025 07:56 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Vir Biotechnology NASDAQ:VIR

$5.41 -0.08 (-1.46%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.41 0.00 (0.00%)

As of 07/18/2025 06:39 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time